Jane Street’s Galectin Therapeutics GALT Stock Holding History

Jane Street’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$467K	Sell	167,400 -12,900	-7%	-$39.2K	﹤0.01%	8221
2025 Q4	$750K	Buy	+180,300	New	+$949K	﹤0.01%	6782
2025 Q1	–	Sell	-89,500	Closed	-$115K	–	9808
2024 Q4	$115K	Buy	+89,500	New	+$214K	﹤0.01%	8708
2022 Q1	–	Sell	-42,100	Closed	-$87K	–	10535
2021 Q4	$87K	Sell	42,100 -5,000	-11%	-$14.3K	﹤0.01%	9309
2021 Q3	$183K	Buy	47,100 +34,500	+274%	+$117K	﹤0.01%	8920
2021 Q2	$40K	Buy	+12,600	New	+$44.8K	﹤0.01%	9545

Other funds holding GALT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Jane Street's GALT Position: Q1 2026 in Review

Jane Street reduced its Galectin Therapeutics (GALT) stake by 2.2% in Q1 2026, selling an estimated $13.6K and leaving 194,868 shares worth $544K. The position accounts for ﹤0.01% of the portfolio, ranked #7848.

Jane Street first reported a position in GALT in Q3 2013 and has held it in 15 quarters since. The position peaked at $1.58M in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Jane Street held 194,868 shares of Galectin Therapeutics worth $544K as of Q1 2026.
Jane Street sold 4,471 Galectin Therapeutics shares in Q1 2026, an estimated $13.6K.
Galectin Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7848 holding.
Jane Street first reported a position in Galectin Therapeutics in Q3 2013 and has held it in 15 quarters since.
Jane Street's Galectin Therapeutics position peaked at $1.58M in Q2 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.